ASX-Dividend-Report-Banner

Siriraj Hospital Expands Services to Provide Advanced Medical Care, Highlights State-of-the-Art Technology for Cancer Treatment

February 26, 2024 11:00 AM AEDT | By Cision
 Siriraj Hospital Expands Services to Provide Advanced Medical Care, Highlights State-of-the-Art Technology for Cancer Treatment
Image source: Kalkine Media

BANGKOK, Feb. 26, 2024 /PRNewswire/ -- Cancer continues to be one of the major health crises globally and in Thailand. Siriraj Hospital, recognized as one of the largest and leading hospitals in Thailand, demonstrates its readiness and dedication to delivering comprehensive medical services, including advanced cancer treatment, for both Thai and international patients.

The Unity MR LINAC
The Unity MR LINAC

Siriraj Hospital is enhancing its cancer services with advanced medical equipment, including the Magnetic Resonance Linear Accelerator (MR LINAC), and a highly skilled oncology team. Equipped with modern devices, Siriraj oncology specialists are dedicated to providing personalized care for patients with various types of cancer.

Cancer is the second leading cause of death globally, claiming some 9.9 million lives in 2020. In the World Health Organization (WHO) Southeast Asia Region, 1.4 million died of the disease. While advancements have been achieved in various facets of cancer treatment, including Robotic-Assisted Surgery, immunotherapy, and targeted chemotherapy, major strides have been particularly notable in the field of radiotherapy.

The Siriraj Center of Radiation Oncology (SiRO) is the first and only medical institution in Thailand and Southeast Asia to install the UNITY® 1.5T MRI 7MV-Linear accelerator. This MR LINAC system at SiRO offers advanced precision radiotherapy capabilities, enhancing treatment options for patients in Thailand.

The MR LINAC technology seamlessly integrates a magnetic resonance imaging (MRI) scanner and a linear accelerator, providing enhanced control over radiation delivery. This innovative system offers high-definition imaging for precise tumor targeting, with the MRI guiding the process while the linear accelerator delivers high-dose radiation to eliminate cancer cells. This real-time visualization capability contributes to effective therapy. The MR LINAC is well-suited for patients with tumors in the liver, prostate, gastrointestinal organs, and urinary and reproductive tracts. The MR LINAC at SiRO has treated more than 400 patients since commencing operations in October 2020. This will greatly benefit patients—both Thai and foreign—seeking access to the groundbreaking treatment. 

Associate Professor Pittaya Dankulchai, Head of Radiotherapy Division, Department of Radiology, Faculty of Medicine Siriraj Hospital, shared his stance, "The MR LINAC is transforming the landscape of cancer treatment by combining the power of MRI technology with state-of-the-art radiotherapy. This innovation gives us the advanced capabilities to visualize and adapt treatment plans in real-time, offering pinpoint precision for each patient's treatment, marking a significant stride forward in the battle against cancer,"

Siriraj Hospital further underlines its commitment to cancer research and has made breakthroughs in Chimeric Antigen Receptor (CAR)-T cell therapy for a vastly complex cancer such as acute lymphoblastic leukemia and multiple myeloma. The treatment is a revolutionary form of immunotherapy for cancer treatment involving the genetic modification of immune system cells, particularly T cells, from either the patient or a donor. This modification empowers these cells with enhanced precision, allowing them to identify and attack cancer cells more effectively—an innovative approach likened to equipping cells with potent weapons to combat specific cancer targets.

Dr Smith Kungwankiattichai, M.D, Lecturer, Division of Hematology, Faculty of Medicine Siriraj Hospital, said, "CAR T cell therapy at Siriraj Hospital is a testament to the collaborative efforts between Siriraj Hospital's Hematology Division, Department of Internal Medicine, and the Siriraj Center of Excellence for Stem Cell Research (SISCR). Research on the efficacy and safety of CAR T cells manufactured at Siriraj Hospital started in March 2023. We aim to eventually make the very high-cost CAR T cell therapy more accessible and a standard treatment option in Thailand for patients with hematologic malignancies and multiple myeloma. Our advanced facilities, coupled with a dedicated team of experts, showcase our commitment to providing top-tier medical services. Through continuous innovation, collaborative research, and cutting-edge technologies, we ensure that each patient receives compassionate, advanced care and healthcare experience." 

Contact information:
Siriraj Cancer Center https://www4.si.mahidol.ac.th/th/department/cancer/index.php
Tel. : +662-419 4471-2
Email : [email protected]

About Siriraj Hospital

Established in 1888, Siriraj Hospital is Thailand's oldest and largest healthcare institution, affiliated with the prestigious Faculty of Medicine at Siriraj Hospital, Mahidol University. As a leading specialist referral hospital, it annually trains 300 medical students, fostering the next generation of healthcare professionals. With a capacity of over 2,000 beds, the hospital provides advanced medical services to more than three million patients annually. Its legacy is rooted in a commitment to excellence, compassion, and innovation. Siriraj Hospital continues to be a pillar of healthcare in Thai society, blending tradition with modernity to provide exceptional medical care for the community.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.